APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Medications for Multiple Sclerosis

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Oral Medications for Multiple Sclerosis Market Outlook and Growth Opportunities 2026

27 December 2025213 pages

Choose your research edition.

Industry ResearchOral Medications for Multiple Sclerosis Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Medications for Multiple Sclerosis Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Oral Medications for Multiple Sclerosis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Medications for Multiple Sclerosis Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Medications for Multiple Sclerosis Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Oral Medications for Multiple Sclerosis market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Oral Medications for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oral Medications for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral Medications for Multiple Sclerosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Oral Medications for Multiple Sclerosis market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Oral Medications for Multiple Sclerosis market include Sichuan Omnis Pharmaceutical, CGeneTech (Suzhou, China), Qilu Pharmaceutical, Nanjing Healthnice Pharmaceutical, HEC Pharm, Cisen Pharmaceutical, Zydus, Viatris and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Oral Medications for Multiple Sclerosis market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oral Medications for Multiple Sclerosis and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oral Medications for Multiple Sclerosis sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oral Medications for Multiple Sclerosis market size, projected growth trends, production technologies, key applications, and end-use industries.

Oral Medications for Multiple Sclerosis Segment by Company

Sichuan Omnis Pharmaceutical

CGeneTech (Suzhou, China)

Qilu Pharmaceutical

Nanjing Healthnice Pharmaceutical

HEC Pharm

Cisen Pharmaceutical

Zydus

Viatris

Teva

Sun Pharmaceuticals

Sanofi

Sandoz

Novartis

Mylan

Merck

Janssen

Glenmark Pharmaceuticals

Dr. Reddy's Laboratories

Bristol Myers Squibb

Biogen

Banner Life Sciences

Apotex

Alembic

Accord Healthcare

Oral Medications for Multiple Sclerosis Segment by Type

Ozanimod

Ponesimod

Fingolimod

Diroximel Fumarate

Monomethyl Fumarate

Dimethyl Fumarate

Cladribine

Teriflunomide

Siponimod

Oral Medications for Multiple Sclerosis Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Oral Medications for Multiple Sclerosis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Oral Medications for Multiple Sclerosis status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Oral Medications for Multiple Sclerosis market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oral Medications for Multiple Sclerosis significant trends, drivers, influence factors in global and regions.

6. To analyze Oral Medications for Multiple Sclerosis competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Medications for Multiple Sclerosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Medications for Multiple Sclerosis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Medications for Multiple Sclerosis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oral Medications for Multiple Sclerosis market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oral Medications for Multiple Sclerosis industry.

Chapter 3: Detailed analysis of Oral Medications for Multiple Sclerosis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Oral Medications for Multiple Sclerosis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Oral Medications for Multiple Sclerosis in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oral Medications for Multiple Sclerosis Industry Trends Table 2. Oral Medications for Multiple Sclerosis Industry Drivers Table 3. Oral Medications for Multiple Sclerosis Industry Opportunities and Challenges Table 4. Oral Medications for Multiple Sclerosis Industry Restraints Table 5. Global Oral Medications for Multiple Sclerosis Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oral Medications for Multiple Sclerosis Revenue Share by Company (2021-2026) Table 7. Global Oral Medications for Multiple Sclerosis Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Oral Medications for Multiple Sclerosis Sales Volume Share by Company (2021-2026) Table 9. Global Oral Medications for Multiple Sclerosis Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Oral Medications for Multiple Sclerosis Company Ranking, (2024-2026) & (USD Million) Table 11. Global Oral Medications for Multiple Sclerosis Key Company Manufacturing Base & Headquarters Table 12. Global Oral Medications for Multiple Sclerosis Company, Product Type & Application Table 13. Global Oral Medications for Multiple Sclerosis Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Oral Medications for Multiple Sclerosis by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Ozanimod Table 18. Significant Companies of Ponesimod Table 19. Significant Companies of Fingolimod Table 20. Significant Companies of Diroximel Fumarate Table 21. Significant Companies of Monomethyl Fumarate Table 22. Significant Companies of Dimethyl Fumarate Table 23. Significant Companies of Cladribine Table 24. Significant Companies of Teriflunomide Table 25. Significant Companies of Siponimod Table 26. Global Oral Medications for Multiple Sclerosis Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Oral Medications for Multiple Sclerosis Sales Volume by Type (2021-2026) & (K Units) Table 28. Global Oral Medications for Multiple Sclerosis Sales Volume by Type (2027-2032) & (K Units) Table 29. Global Oral Medications for Multiple Sclerosis Sales Volume Share by Type (2021-2026) Table 30. Global Oral Medications for Multiple Sclerosis Sales Volume Share by Type (2027-2032) Table 31. Global Oral Medications for Multiple Sclerosis Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Oral Medications for Multiple Sclerosis Sales Value by Type (2021-2026) & (US$ Million) Table 33. Global Oral Medications for Multiple Sclerosis Sales Value by Type (2027-2032) & (US$ Million) Table 34. Global Oral Medications for Multiple Sclerosis Sales Value Share by Type (2021-2026) Table 35. Global Oral Medications for Multiple Sclerosis Sales Value Share by Type (2027-2032) Table 36. Significant Companies of Hospital and Clinic Table 37. Significant Companies of Retail Pharmacies Table 38. Significant Companies of Other Table 39. Global Oral Medications for Multiple Sclerosis Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Oral Medications for Multiple Sclerosis Sales Volume by Application (2021-2026) & (K Units) Table 41. Global Oral Medications for Multiple Sclerosis Sales Volume by Application (2027-2032) & (K Units) Table 42. Global Oral Medications for Multiple Sclerosis Sales Volume Share by Application (2021-2026) Table 43. Global Oral Medications for Multiple Sclerosis Sales Volume Share by Application (2027-2032) Table 44. Global Oral Medications for Multiple Sclerosis Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Oral Medications for Multiple Sclerosis Sales Value by Application (2021-2026) & (US$ Million) Table 46. Global Oral Medications for Multiple Sclerosis Sales Value by Application (2027-2032) & (US$ Million) Table 47. Global Oral Medications for Multiple Sclerosis Sales Value Share by Application (2021-2026) Table 48. Global Oral Medications for Multiple Sclerosis Sales Value Share by Application (2027-2032) Table 49. Global Oral Medications for Multiple Sclerosis Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 50. Global Oral Medications for Multiple Sclerosis Sales by Region (2021-2026) & (K Units) Table 51. Global Oral Medications for Multiple Sclerosis Sales Market Share by Region (2021-2026) Table 52. Global Oral Medications for Multiple Sclerosis Sales by Region (2027-2032) & (K Units) Table 53. Global Oral Medications for Multiple Sclerosis Sales Market Share by Region (2027-2032) Table 54. Global Oral Medications for Multiple Sclerosis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Oral Medications for Multiple Sclerosis Sales Value by Region (2021-2026) & (US$ Million) Table 56. Global Oral Medications for Multiple Sclerosis Sales Value Share by Region (2021-2026) Table 57. Global Oral Medications for Multiple Sclerosis Sales Value by Region (2027-2032) & (US$ Million) Table 58. Global Oral Medications for Multiple Sclerosis Sales Value Share by Region (2027-2032) Table 59. Global Oral Medications for Multiple Sclerosis Market Average Price (US$/Unit) by Region (2021-2026) Table 60. Global Oral Medications for Multiple Sclerosis Market Average Price (US$/Unit) by Region (2027-2032) Table 61. Global Oral Medications for Multiple Sclerosis Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 62. Global Oral Medications for Multiple Sclerosis Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Oral Medications for Multiple Sclerosis Sales by Country (2021-2026) & (K Units) Table 64. Global Oral Medications for Multiple Sclerosis Sales Market Share by Country (2021-2026) Table 65. Global Oral Medications for Multiple Sclerosis Sales by Country (2027-2032) & (K Units) Table 66. Global Oral Medications for Multiple Sclerosis Sales Market Share by Country (2027-2032) Table 67. Global Oral Medications for Multiple Sclerosis Sales Value by Country (2021-2026) & (US$ Million) Table 68. Global Oral Medications for Multiple Sclerosis Sales Value Market Share by Country (2021-2026) Table 69. Global Oral Medications for Multiple Sclerosis Sales Value by Country (2027-2032) & (US$ Million) Table 70. Global Oral Medications for Multiple Sclerosis Sales Value Market Share by Country (2027-2032) Table 71. Sichuan Omnis Pharmaceutical Company Information Table 72. Sichuan Omnis Pharmaceutical Business Overview Table 73. Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio Table 75. Sichuan Omnis Pharmaceutical Recent Development Table 76. CGeneTech (Suzhou, China) Company Information Table 77. CGeneTech (Suzhou, China) Business Overview Table 78. CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Product Portfolio Table 80. CGeneTech (Suzhou, China) Recent Development Table 81. Qilu Pharmaceutical Company Information Table 82. Qilu Pharmaceutical Business Overview Table 83. Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio Table 85. Qilu Pharmaceutical Recent Development Table 86. Nanjing Healthnice Pharmaceutical Company Information Table 87. Nanjing Healthnice Pharmaceutical Business Overview Table 88. Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio Table 90. Nanjing Healthnice Pharmaceutical Recent Development Table 91. HEC Pharm Company Information Table 92. HEC Pharm Business Overview Table 93. HEC Pharm Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. HEC Pharm Oral Medications for Multiple Sclerosis Product Portfolio Table 95. HEC Pharm Recent Development Table 96. Cisen Pharmaceutical Company Information Table 97. Cisen Pharmaceutical Business Overview Table 98. Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio Table 100. Cisen Pharmaceutical Recent Development Table 101. Zydus Company Information Table 102. Zydus Business Overview Table 103. Zydus Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Zydus Oral Medications for Multiple Sclerosis Product Portfolio Table 105. Zydus Recent Development Table 106. Viatris Company Information Table 107. Viatris Business Overview Table 108. Viatris Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Viatris Oral Medications for Multiple Sclerosis Product Portfolio Table 110. Viatris Recent Development Table 111. Teva Company Information Table 112. Teva Business Overview Table 113. Teva Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Teva Oral Medications for Multiple Sclerosis Product Portfolio Table 115. Teva Recent Development Table 116. Sun Pharmaceuticals Company Information Table 117. Sun Pharmaceuticals Business Overview Table 118. Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio Table 120. Sun Pharmaceuticals Recent Development Table 121. Sanofi Company Information Table 122. Sanofi Business Overview Table 123. Sanofi Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Sanofi Oral Medications for Multiple Sclerosis Product Portfolio Table 125. Sanofi Recent Development Table 126. Sandoz Company Information Table 127. Sandoz Business Overview Table 128. Sandoz Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Sandoz Oral Medications for Multiple Sclerosis Product Portfolio Table 130. Sandoz Recent Development Table 131. Novartis Company Information Table 132. Novartis Business Overview Table 133. Novartis Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Novartis Oral Medications for Multiple Sclerosis Product Portfolio Table 135. Novartis Recent Development Table 136. Mylan Company Information Table 137. Mylan Business Overview Table 138. Mylan Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Mylan Oral Medications for Multiple Sclerosis Product Portfolio Table 140. Mylan Recent Development Table 141. Merck Company Information Table 142. Merck Business Overview Table 143. Merck Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Merck Oral Medications for Multiple Sclerosis Product Portfolio Table 145. Merck Recent Development Table 146. Janssen Company Information Table 147. Janssen Business Overview Table 148. Janssen Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Janssen Oral Medications for Multiple Sclerosis Product Portfolio Table 150. Janssen Recent Development Table 151. Glenmark Pharmaceuticals Company Information Table 152. Glenmark Pharmaceuticals Business Overview Table 153. Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio Table 155. Glenmark Pharmaceuticals Recent Development Table 156. Dr. Reddy's Laboratories Company Information Table 157. Dr. Reddy's Laboratories Business Overview Table 158. Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 159. Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Product Portfolio Table 160. Dr. Reddy's Laboratories Recent Development Table 161. Bristol Myers Squibb Company Information Table 162. Bristol Myers Squibb Business Overview Table 163. Bristol Myers Squibb Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 164. Bristol Myers Squibb Oral Medications for Multiple Sclerosis Product Portfolio Table 165. Bristol Myers Squibb Recent Development Table 166. Biogen Company Information Table 167. Biogen Business Overview Table 168. Biogen Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 169. Biogen Oral Medications for Multiple Sclerosis Product Portfolio Table 170. Biogen Recent Development Table 171. Banner Life Sciences Company Information Table 172. Banner Life Sciences Business Overview Table 173. Banner Life Sciences Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 174. Banner Life Sciences Oral Medications for Multiple Sclerosis Product Portfolio Table 175. Banner Life Sciences Recent Development Table 176. Apotex Company Information Table 177. Apotex Business Overview Table 178. Apotex Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 179. Apotex Oral Medications for Multiple Sclerosis Product Portfolio Table 180. Apotex Recent Development Table 181. Alembic Company Information Table 182. Alembic Business Overview Table 183. Alembic Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 184. Alembic Oral Medications for Multiple Sclerosis Product Portfolio Table 185. Alembic Recent Development Table 186. Accord Healthcare Company Information Table 187. Accord Healthcare Business Overview Table 188. Accord Healthcare Oral Medications for Multiple Sclerosis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 189. Accord Healthcare Oral Medications for Multiple Sclerosis Product Portfolio Table 190. Accord Healthcare Recent Development Table 191. Key Raw Materials Table 192. Raw Materials Key Suppliers Table 193. Oral Medications for Multiple Sclerosis Distributors List Table 194. Oral Medications for Multiple Sclerosis Customers List Table 195. Research Programs/Design for This Report Table 196. Authors List of This Report Table 197. Secondary Sources Table 198. Primary Sources List of Figures Figure 1. Oral Medications for Multiple Sclerosis Product Image Figure 2. Global Oral Medications for Multiple Sclerosis Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Medications for Multiple Sclerosis Sales Value (2021-2032) & (US$ Million) Figure 4. Global Oral Medications for Multiple Sclerosis Sales (2021-2032) & (K Units) Figure 5. Global Oral Medications for Multiple Sclerosis Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Oral Medications for Multiple Sclerosis Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Ozanimod Image Figure 10. Ponesimod Image Figure 11. Fingolimod Image Figure 12. Diroximel Fumarate Image Figure 13. Monomethyl Fumarate Image Figure 14. Dimethyl Fumarate Image Figure 15. Cladribine Image Figure 16. Teriflunomide Image Figure 17. Siponimod Image Figure 18. Global Oral Medications for Multiple Sclerosis Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Oral Medications for Multiple Sclerosis Sales Volume Share 2021 VS 2025 VS 2032 Figure 20. Global Oral Medications for Multiple Sclerosis Sales Volume Share by Type (2021-2032) Figure 21. Global Oral Medications for Multiple Sclerosis Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Oral Medications for Multiple Sclerosis Sales Value Share 2021 VS 2025 VS 2032 Figure 23. Global Oral Medications for Multiple Sclerosis Sales Value Share by Type (2021-2032) Figure 24. Hospital and Clinic Image Figure 25. Retail Pharmacies Image Figure 26. Other Image Figure 27. Global Oral Medications for Multiple Sclerosis Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Oral Medications for Multiple Sclerosis Sales Volume Share 2021 VS 2025 VS 2032 Figure 29. Global Oral Medications for Multiple Sclerosis Sales Volume Share by Application (2021-2032) Figure 30. Global Oral Medications for Multiple Sclerosis Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Oral Medications for Multiple Sclerosis Sales Value Share 2021 VS 2025 VS 2032 Figure 32. Global Oral Medications for Multiple Sclerosis Sales Value Share by Application (2021-2032) Figure 33. Global Oral Medications for Multiple Sclerosis Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 34. Global Oral Medications for Multiple Sclerosis Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 35. Global Oral Medications for Multiple Sclerosis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 36. Global Oral Medications for Multiple Sclerosis Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 37. North America Oral Medications for Multiple Sclerosis Sales Value (2021-2032) & (US$ Million) Figure 38. North America Oral Medications for Multiple Sclerosis Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Europe Oral Medications for Multiple Sclerosis Sales Value (2021-2032) & (US$ Million) Figure 40. Europe Oral Medications for Multiple Sclerosis Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Asia-Pacific Oral Medications for Multiple Sclerosis Sales Value (2021-2032) & (US$ Million) Figure 42. Asia-Pacific Oral Medications for Multiple Sclerosis Sales Value Share by Country (%), 2025 VS 2032 Figure 43. South America Oral Medications for Multiple Sclerosis Sales Value (2021-2032) & (US$ Million) Figure 44. South America Oral Medications for Multiple Sclerosis Sales Value Share by Country (%), 2025 VS 2032 Figure 45. Middle East & Africa Oral Medications for Multiple Sclerosis Sales Value (2021-2032) & (US$ Million) Figure 46. Middle East & Africa Oral Medications for Multiple Sclerosis Sales Value Share by Country (%), 2025 VS 2032 Figure 47. USA Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. USA Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. USA Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Canada Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Canada Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Canada Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Mexico Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Mexico Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Mexico Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Germany Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Germany Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Germany Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. France Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. France Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. France Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. U.K. Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. U.K. Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. U.K. Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Italy Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Italy Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Italy Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Spain Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Spain Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Spain Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Russia Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Russia Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Russia Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Netherlands Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Netherlands Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Netherlands Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Nordic Countries Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Nordic Countries Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Nordic Countries Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. China Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. China Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. China Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Japan Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Japan Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Japan Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. South Korea Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. South Korea Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. South Korea Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. India Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. India Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. India Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Australia Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Australia Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Australia Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Southeast Asia Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Southeast Asia Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Southeast Asia Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Brazil Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Brazil Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Brazil Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Argentina Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Argentina Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Argentina Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Chile Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Chile Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Chile Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Colombia Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Colombia Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Colombia Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Peru Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Peru Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Peru Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Saudi Arabia Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Saudi Arabia Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Israel Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Israel Arabia Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Israel Arabia Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. UAE Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. UAE Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. UAE Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Turkey Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Turkey Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Turkey Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Iran Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Iran Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Iran Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Egypt Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 129. Egypt Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 130. Egypt Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 131. Oral Medications for Multiple Sclerosis Value Chain Figure 132. Manufacturing Cost Structure Figure 133. Oral Medications for Multiple Sclerosis Sales Mode & Process Figure 134. Direct Comparison with Distribution Share Figure 135. Distributors Profiles Figure 136. Years Considered Figure 137. Research Process Figure 138. Key Executives Interviewed

Scope & coverage.

Types
  • Ozanimod
  • Ponesimod
  • Fingolimod
  • Diroximel Fumarate
  • Monomethyl Fumarate
  • Dimethyl Fumarate
  • Cladribine
  • Teriflunomide
  • Siponimod
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Sichuan Omnis Pharmaceutical
  • CGeneTech (Suzhou, China)
  • Qilu Pharmaceutical
  • Nanjing Healthnice Pharmaceutical
  • HEC Pharm
  • Cisen Pharmaceutical
  • Zydus
  • Viatris
  • Teva
  • Sun Pharmaceuticals
  • Sanofi
  • Sandoz
  • Novartis
  • Mylan
  • Merck
  • Janssen
  • Glenmark Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Bristol Myers Squibb
  • Biogen
  • Banner Life Sciences
  • Apotex
  • Alembic
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Oral Medications for Multiple Sclerosis Sales Value (2021-2032)
  4. 1.2.2 Global Oral Medications for Multiple Sclerosis Sales Volume (2021-2032)
  5. 1.2.3 Global Oral Medications for Multiple Sclerosis Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Oral Medications for Multiple Sclerosis Market Dynamics
  1. 2.1 Oral Medications for Multiple Sclerosis Industry Trends
  2. 2.2 Oral Medications for Multiple Sclerosis Industry Drivers
  3. 2.3 Oral Medications for Multiple Sclerosis Industry Opportunities and Challenges
  4. 2.4 Oral Medications for Multiple Sclerosis Industry Restraints
3 Oral Medications for Multiple Sclerosis Market by Company
  1. 3.1 Global Oral Medications for Multiple Sclerosis Company Revenue Ranking in 2025
  2. 3.2 Global Oral Medications for Multiple Sclerosis Revenue by Company (2021-2026)
  3. 3.3 Global Oral Medications for Multiple Sclerosis Sales Volume by Company (2021-2026)
  4. 3.4 Global Oral Medications for Multiple Sclerosis Average Price by Company (2021-2026)
  5. 3.5 Global Oral Medications for Multiple Sclerosis Company Ranking (2024-2026)
  6. 3.6 Global Oral Medications for Multiple Sclerosis Company Manufacturing Base and Headquarters
  7. 3.7 Global Oral Medications for Multiple Sclerosis Company Product Type and Application
  8. 3.8 Global Oral Medications for Multiple Sclerosis Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Oral Medications for Multiple Sclerosis Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Oral Medications for Multiple Sclerosis Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Oral Medications for Multiple Sclerosis Market by Type
  1. 4.1 Oral Medications for Multiple Sclerosis Type Introduction
  2. 4.1.1 Ozanimod
  3. 4.1.2 Ponesimod
  4. 4.1.3 Fingolimod
  5. 4.1.4 Diroximel Fumarate
  6. 4.1.5 Monomethyl Fumarate
  7. 4.1.6 Dimethyl Fumarate
  8. 4.1.7 Cladribine
  9. 4.1.8 Teriflunomide
  10. 4.1.9 Siponimod
  11. 4.2 Global Oral Medications for Multiple Sclerosis Sales Volume by Type
  12. 4.2.1 Global Oral Medications for Multiple Sclerosis Sales Volume by Type (2021 VS 2025 VS 2032)
  13. 4.2.2 Global Oral Medications for Multiple Sclerosis Sales Volume by Type (2021-2032)
  14. 4.2.3 Global Oral Medications for Multiple Sclerosis Sales Volume Share by Type (2021-2032)
  15. 4.3 Global Oral Medications for Multiple Sclerosis Sales Value by Type
  16. 4.3.1 Global Oral Medications for Multiple Sclerosis Sales Value by Type (2021 VS 2025 VS 2032)
  17. 4.3.2 Global Oral Medications for Multiple Sclerosis Sales Value by Type (2021-2032)
  18. 4.3.3 Global Oral Medications for Multiple Sclerosis Sales Value Share by Type (2021-2032)
5 Oral Medications for Multiple Sclerosis Market by Application
  1. 5.1 Oral Medications for Multiple Sclerosis Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Oral Medications for Multiple Sclerosis Sales Volume by Application
  6. 5.2.1 Global Oral Medications for Multiple Sclerosis Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Oral Medications for Multiple Sclerosis Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Oral Medications for Multiple Sclerosis Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Oral Medications for Multiple Sclerosis Sales Value by Application
  10. 5.3.1 Global Oral Medications for Multiple Sclerosis Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Oral Medications for Multiple Sclerosis Sales Value by Application (2021-2032)
  12. 5.3.3 Global Oral Medications for Multiple Sclerosis Sales Value Share by Application (2021-2032)
6 Oral Medications for Multiple Sclerosis Regional Sales and Value Analysis
  1. 6.1 Global Oral Medications for Multiple Sclerosis Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oral Medications for Multiple Sclerosis Sales by Region (2021-2032)
  3. 6.2.1 Global Oral Medications for Multiple Sclerosis Sales by Region: 2021-2026
  4. 6.2.2 Global Oral Medications for Multiple Sclerosis Sales by Region (2027-2032)
  5. 6.3 Global Oral Medications for Multiple Sclerosis Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Oral Medications for Multiple Sclerosis Sales Value by Region (2021-2032)
  7. 6.4.1 Global Oral Medications for Multiple Sclerosis Sales Value by Region: 2021-2026
  8. 6.4.2 Global Oral Medications for Multiple Sclerosis Sales Value by Region (2027-2032)
  9. 6.5 Global Oral Medications for Multiple Sclerosis Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Oral Medications for Multiple Sclerosis Sales Value (2021-2032)
  12. 6.6.2 North America Oral Medications for Multiple Sclerosis Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Oral Medications for Multiple Sclerosis Sales Value (2021-2032)
  15. 6.7.2 Europe Oral Medications for Multiple Sclerosis Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Oral Medications for Multiple Sclerosis Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Oral Medications for Multiple Sclerosis Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Oral Medications for Multiple Sclerosis Sales Value (2021-2032)
  21. 6.9.2 South America Oral Medications for Multiple Sclerosis Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Oral Medications for Multiple Sclerosis Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Oral Medications for Multiple Sclerosis Sales Value Share by Country, 2025 VS 2032
7 Oral Medications for Multiple Sclerosis Country-level Sales and Value Analysis
  1. 7.1 Global Oral Medications for Multiple Sclerosis Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oral Medications for Multiple Sclerosis Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Oral Medications for Multiple Sclerosis Sales by Country (2021-2032)
  4. 7.3.1 Global Oral Medications for Multiple Sclerosis Sales by Country (2021-2026)
  5. 7.3.2 Global Oral Medications for Multiple Sclerosis Sales by Country (2027-2032)
  6. 7.4 Global Oral Medications for Multiple Sclerosis Sales Value by Country (2021-2032)
  7. 7.4.1 Global Oral Medications for Multiple Sclerosis Sales Value by Country (2021-2026)
  8. 7.4.2 Global Oral Medications for Multiple Sclerosis Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Oral Medications for Multiple Sclerosis Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Oral Medications for Multiple Sclerosis Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Oral Medications for Multiple Sclerosis Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sichuan Omnis Pharmaceutical
  2. 8.1.1 Sichuan Omnis Pharmaceutical Company Information
  3. 8.1.2 Sichuan Omnis Pharmaceutical Business Overview
  4. 8.1.3 Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
  6. 8.1.5 Sichuan Omnis Pharmaceutical Recent Developments
  7. 8.2 CGeneTech (Suzhou, China)
  8. 8.2.1 CGeneTech (Suzhou, China) Company Information
  9. 8.2.2 CGeneTech (Suzhou, China) Business Overview
  10. 8.2.3 CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Product Portfolio
  12. 8.2.5 CGeneTech (Suzhou, China) Recent Developments
  13. 8.3 Qilu Pharmaceutical
  14. 8.3.1 Qilu Pharmaceutical Company Information
  15. 8.3.2 Qilu Pharmaceutical Business Overview
  16. 8.3.3 Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
  18. 8.3.5 Qilu Pharmaceutical Recent Developments
  19. 8.4 Nanjing Healthnice Pharmaceutical
  20. 8.4.1 Nanjing Healthnice Pharmaceutical Company Information
  21. 8.4.2 Nanjing Healthnice Pharmaceutical Business Overview
  22. 8.4.3 Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
  24. 8.4.5 Nanjing Healthnice Pharmaceutical Recent Developments
  25. 8.5 HEC Pharm
  26. 8.5.1 HEC Pharm Company Information
  27. 8.5.2 HEC Pharm Business Overview
  28. 8.5.3 HEC Pharm Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 HEC Pharm Oral Medications for Multiple Sclerosis Product Portfolio
  30. 8.5.5 HEC Pharm Recent Developments
  31. 8.6 Cisen Pharmaceutical
  32. 8.6.1 Cisen Pharmaceutical Company Information
  33. 8.6.2 Cisen Pharmaceutical Business Overview
  34. 8.6.3 Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
  36. 8.6.5 Cisen Pharmaceutical Recent Developments
  37. 8.7 Zydus
  38. 8.7.1 Zydus Company Information
  39. 8.7.2 Zydus Business Overview
  40. 8.7.3 Zydus Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Zydus Oral Medications for Multiple Sclerosis Product Portfolio
  42. 8.7.5 Zydus Recent Developments
  43. 8.8 Viatris
  44. 8.8.1 Viatris Company Information
  45. 8.8.2 Viatris Business Overview
  46. 8.8.3 Viatris Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Viatris Oral Medications for Multiple Sclerosis Product Portfolio
  48. 8.8.5 Viatris Recent Developments
  49. 8.9 Teva
  50. 8.9.1 Teva Company Information
  51. 8.9.2 Teva Business Overview
  52. 8.9.3 Teva Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Teva Oral Medications for Multiple Sclerosis Product Portfolio
  54. 8.9.5 Teva Recent Developments
  55. 8.10 Sun Pharmaceuticals
  56. 8.10.1 Sun Pharmaceuticals Company Information
  57. 8.10.2 Sun Pharmaceuticals Business Overview
  58. 8.10.3 Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio
  60. 8.10.5 Sun Pharmaceuticals Recent Developments
  61. 8.11 Sanofi
  62. 8.11.1 Sanofi Company Information
  63. 8.11.2 Sanofi Business Overview
  64. 8.11.3 Sanofi Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Sanofi Oral Medications for Multiple Sclerosis Product Portfolio
  66. 8.11.5 Sanofi Recent Developments
  67. 8.12 Sandoz
  68. 8.12.1 Sandoz Company Information
  69. 8.12.2 Sandoz Business Overview
  70. 8.12.3 Sandoz Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Sandoz Oral Medications for Multiple Sclerosis Product Portfolio
  72. 8.12.5 Sandoz Recent Developments
  73. 8.13 Novartis
  74. 8.13.1 Novartis Company Information
  75. 8.13.2 Novartis Business Overview
  76. 8.13.3 Novartis Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Novartis Oral Medications for Multiple Sclerosis Product Portfolio
  78. 8.13.5 Novartis Recent Developments
  79. 8.14 Mylan
  80. 8.14.1 Mylan Company Information
  81. 8.14.2 Mylan Business Overview
  82. 8.14.3 Mylan Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Mylan Oral Medications for Multiple Sclerosis Product Portfolio
  84. 8.14.5 Mylan Recent Developments
  85. 8.15 Merck
  86. 8.15.1 Merck Company Information
  87. 8.15.2 Merck Business Overview
  88. 8.15.3 Merck Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Merck Oral Medications for Multiple Sclerosis Product Portfolio
  90. 8.15.5 Merck Recent Developments
  91. 8.16 Janssen
  92. 8.16.1 Janssen Company Information
  93. 8.16.2 Janssen Business Overview
  94. 8.16.3 Janssen Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Janssen Oral Medications for Multiple Sclerosis Product Portfolio
  96. 8.16.5 Janssen Recent Developments
  97. 8.17 Glenmark Pharmaceuticals
  98. 8.17.1 Glenmark Pharmaceuticals Company Information
  99. 8.17.2 Glenmark Pharmaceuticals Business Overview
  100. 8.17.3 Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio
  102. 8.17.5 Glenmark Pharmaceuticals Recent Developments
  103. 8.18 Dr. Reddy's Laboratories
  104. 8.18.1 Dr. Reddy's Laboratories Company Information
  105. 8.18.2 Dr. Reddy's Laboratories Business Overview
  106. 8.18.3 Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Product Portfolio
  108. 8.18.5 Dr. Reddy's Laboratories Recent Developments
  109. 8.19 Bristol Myers Squibb
  110. 8.19.1 Bristol Myers Squibb Company Information
  111. 8.19.2 Bristol Myers Squibb Business Overview
  112. 8.19.3 Bristol Myers Squibb Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Bristol Myers Squibb Oral Medications for Multiple Sclerosis Product Portfolio
  114. 8.19.5 Bristol Myers Squibb Recent Developments
  115. 8.20 Biogen
  116. 8.20.1 Biogen Company Information
  117. 8.20.2 Biogen Business Overview
  118. 8.20.3 Biogen Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Biogen Oral Medications for Multiple Sclerosis Product Portfolio
  120. 8.20.5 Biogen Recent Developments
  121. 8.21 Banner Life Sciences
  122. 8.21.1 Banner Life Sciences Company Information
  123. 8.21.2 Banner Life Sciences Business Overview
  124. 8.21.3 Banner Life Sciences Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Banner Life Sciences Oral Medications for Multiple Sclerosis Product Portfolio
  126. 8.21.5 Banner Life Sciences Recent Developments
  127. 8.22 Apotex
  128. 8.22.1 Apotex Company Information
  129. 8.22.2 Apotex Business Overview
  130. 8.22.3 Apotex Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Apotex Oral Medications for Multiple Sclerosis Product Portfolio
  132. 8.22.5 Apotex Recent Developments
  133. 8.23 Alembic
  134. 8.23.1 Alembic Company Information
  135. 8.23.2 Alembic Business Overview
  136. 8.23.3 Alembic Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Alembic Oral Medications for Multiple Sclerosis Product Portfolio
  138. 8.23.5 Alembic Recent Developments
  139. 8.24 Accord Healthcare
  140. 8.24.1 Accord Healthcare Company Information
  141. 8.24.2 Accord Healthcare Business Overview
  142. 8.24.3 Accord Healthcare Oral Medications for Multiple Sclerosis Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Accord Healthcare Oral Medications for Multiple Sclerosis Product Portfolio
  144. 8.24.5 Accord Healthcare Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oral Medications for Multiple Sclerosis Value Chain Analysis
  2. 9.1.1 Oral Medications for Multiple Sclerosis Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oral Medications for Multiple Sclerosis Sales Mode & Process
  6. 9.2 Oral Medications for Multiple Sclerosis Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oral Medications for Multiple Sclerosis Distributors
  9. 9.2.3 Oral Medications for Multiple Sclerosis Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst